BA
LXRX icon

BlackRock Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

BlackRock Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.86M Buy
134,794
+12,972
+11% +$208K ﹤0.01% 1549
2016
Q3 		$2.2M Buy
121,822
+100,969
+484% +$1.62M ﹤0.01% 1428
2016
Q2 		$299K Buy
20,853
+996
+5% +$13.5K ﹤0.01% 2404
2016
Q1 		$237K Buy
19,857
+1,337
+7% +$14K ﹤0.01% 2473
2015
Q4 		$247K Sell
18,520
-8,559
-32% -$105K ﹤0.01% 2458
2015
Q3 		$291K Sell
27,079
-38,895
-59% -$425K ﹤0.01% 2516
2015
Q2 		$531K Buy
65,974
+43,027
+188% +$316K ﹤0.01% 2139
2015
Q1 		$152K Buy
22,947
+3,814
+20% +$26K ﹤0.01% 2839
2014
Q4 		$122K Sell
19,133
-701
-4% -$5.65K ﹤0.01% 2928
2014
Q3 		$196K Sell
19,834
-785
-4% -$8.38K ﹤0.01% 2623
2014
Q2 		$232K Sell
20,619
-3,028
-13% -$32.5K ﹤0.01% 2542
2014
Q1 		$286K Buy
23,647
+1,492
+7% +$19.1K ﹤0.01% 2435
2013
Q4 		$279K Buy
22,155
+1,965
+10% +$31.3K ﹤0.01% 2444
2013
Q3 		$336K Sell
20,190
-5,004
-20% -$83.9K ﹤0.01% 2203
2013
Q2 		$383K Buy
+25,194
New +$383K ﹤0.01% 2026

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's LXRX Position: Q4 2016 in Review

BlackRock Advisors increased its Lexicon Pharmaceuticals (LXRX) stake by 11% in Q4 2016, buying an estimated $208K and bringing the position to 134,794 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1549.

BlackRock Advisors first reported a position in LXRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.2M in Q3 2016. 145 funds tracked by Wall St. Rank hold LXRX as of Q4 2016.

  • BlackRock Advisors held 134,794 shares of Lexicon Pharmaceuticals worth $1.86M as of Q4 2016.
  • BlackRock Advisors bought 12,972 Lexicon Pharmaceuticals shares in Q4 2016, an estimated $208K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1549 holding.
  • BlackRock Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Lexicon Pharmaceuticals position peaked at $2.2M in Q3 2016.
  • 145 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.